SEC 13F Intelligence

Ingalls & Snyder LLC / CORT

Ingalls & Snyder LLC’s Corcept Therapeutics Inc Position

Does Ingalls & Snyder LLC own Corcept Therapeutics Inc (CORT)? Yes — 7.61M shares worth $307M (+10.86% of its 13F portfolio) as of Q1 2026, up from 7.20M shares the prior filed quarter.

Position Value
$307M
Q1 2026
Shares
7.61M
% of Portfolio
+10.86%
Quarters Held
29
currently held

Position History CORT

Reported value by quarter
Q1 ’19: $98MQ1 ’19Q2 ’19: $95MQ3 ’19: $123MQ4 ’19: $97MQ1 ’20: $95MQ1 ’20Q2 ’20: $128MQ3 ’20: $130MQ4 ’20: $191MQ1 ’21: $165MQ1 ’21Q2 ’21: $156MQ3 ’21: $139MQ4 ’21: $133MQ1 ’22: $156MQ1 ’22Q2 ’22: $166MQ3 ’22: $178MQ4 ’22: $139MQ1 ’23: $181MQ1 ’23Q2 ’23: $186MQ3 ’23: $227MQ4 ’23: $271MQ1 ’24: $209MQ1 ’24Q2 ’24: $268MQ3 ’24: $383MQ4 ’24: $408MQ1 ’25: $884MQ1 ’25Q2 ’25: $567MQ3 ’25: $640MQ4 ’25: $250MQ1 ’26: $307MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 20267.61M$307M+10.86%
Q4 20257.20M$250M+9.19%
Q3 20257.70M$640M+20.92%
Q2 20257.72M$567M+20.11%
Q1 20257.74M$884M+29.09%
Q4 20248.10M$408M+16.01%
Q3 20248.27M$383M+14.93%
Q2 20248.24M$268M+11.51%
Q1 20248.30M$209M+9.24%
Q4 20238.35M$271M+12.26%
Q3 20238.34M$227M+10.94%
Q2 20238.36M$186M+8.91%
Q1 20238.37M$181M+9.31%
Q4 20226.83M$139M+7.54%
Q3 20226.95M$178M+9.95%
Q2 20226.99M$166M+8.69%
Q1 20226.91M$156M+6.95%
Q4 20216.74M$133M+6.02%
Q3 20217.05M$139M+6.36%
Q2 20217.07M$156M+6.91%
Q1 20216.95M$165M+7.72%
Q4 20207.30M$191M+9.43%
Q3 20207.49M$130M+8.95%
Q2 20207.60M$128M+7.34%
Q1 20208.00M$95M+6.41%
Q4 20198.01M$97M+5.25%
Q3 20198.71M$123M+6.01%
Q2 20198.52M$95M+4.57%
Q1 20198.37M$98M+4.68%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Ingalls & Snyder LLC’s full portfolio or all institutional holders of CORT.